Home > Newer Agents for Blood Glucose Control...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement)

Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement)

NICE Clinical Guidelines, No. 87S

Norman Waugh, Professor of Public Health, Ewen Cummins, Health Economist, Pam Royle, Information Scientist and Systematic Reviewer, Christine Clar, Systematic Reviewer, Meaghan Marien, Systematic Reviewer, Bernd Richter, Physician and Coordinating Editor, and Sam Philip, Consultant Physician/Diabetologist.

Author Information
Copyright and Permissions

NICE issued an updated guideline (Clinical Guideline 66) for the management of all aspects of type 2 diabetes in May 2008. However new drug developments means that this guideline itself already requires an update. This technology assessment report aims to provide information to support the Short Guideline Development Group (GDG) which will produce a “new drugs update” to the 2008 guideline.

The four classes of drugs which the GDG have been asked to consider are: the glucagon-like peptide 1 analogue, exenatide, in its currently available form, given by injection twice daily (the second drug in that class, liraglutide, was not licensed in time to be included in the guideline update, and nor was the long-acting form of exenatide); the dipeptidyl peptidase 4 inhibitors, sitagliptin and vildagliptin; the long-acting insulin analogues, glargine and detemir (glargine had been the subject of a previous technology appraisal (TA 43) but it was felt that this needed updated and detemir had not previously been appraised by NICE); the thiazolidinediones (hereafter referred to as the glitazones), more from the safety aspects than for glycaemic control.

Contents

A health technology assessment commissioned by the UK Health Technology Assessment Programme in support of the NICE Short Clinical Guidelines Programme.

Project number 08/05/01

Final version March 29th 2009

Acknowledgements

We thank the members of the NICE Short Guideline Development Group, their expert advisor (Professor Anthony Barnett) and the technical team at NICE for useful comments and information during the iterative process which produced this report.

Copyright © 2009, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PMID: 22220324

Download

NICE (National Institute for Health and Care Excellence)

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...